Table 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>Characteristics of patients treated with GEN1046</p>
Publications
7 shownTable 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>Treatment-related AEs reported in >2 patients treated with GEN1046 (<i>n</i> = 61)</p>
Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>GEN1046 antitumor efficacy in patients with advanced solid tumors. <b>A,</b> Waterfall plot of best relative percent change from baseline in tumor size. <...
Figure 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>GEN1046 therapeutic efficacy and antitumor immune responses in MC38-hPD-L1 tumor–bearing hPD-L1/h4-1BB dKI mice. <b>A,</b> MC38-hPD-L1 cells (1 × 10<sup&...
Figure 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>GEN1046 induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity <i>in vitro<...
Figure 3 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>GEN1046 promotes TIL expansion from patient-derived tumor tissue. Tumor tissues resected from patients with NSCLC were cut into pieces of 1 to 2 mm<sup>3</sup&...
Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
<p>Pharmacokinetics and pharmacodynamics of GEN1046 in patients with advanced solid tumors. <b>A,</b> Mean plasma concentration of GEN1046 during the first two...
Frequent Co-Authors
Researcher Info
- h-index
- 0
- Publications
- 7
- Citations
- 0
External Links
Identifiers
- ORCID
- 0000-0002-7716-9838
Impact Metrics
h-index
0
h-index: Number of publications with at least h citations each.